Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.

Since closing its $245m funding raise, Quanta Dialysis Technologies has been scaling up its commercial infrastructure and bolstering its US presence.

Quanta CEO John Milad outlines the transitional stage where a company begins to seek large-scale funding for the first time, and debates market valuations.

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from June.